Wall Street has long treated rising interest rates as a structural headwind for biotechnology equities, but at least one senior analyst is pushing back on that assumption. Jared Holz of Mizuho told CNBC that the Federal Reserve's recent rate increase carries limited structural significance for the sector, and that investors may be overstating the direct influence of monetary policy on drug developers.
Holz's argument rests on a simple observation: markets tend to overstate how much benchmark rates actually shape biotech valuations. In his view, the widely held belief that higher rates naturally suppress drug development valuations is a psychological interpretation rather than a fundamental truth. The iShares Biotechnology ETF has climbed more than 20% year-to-date, a performance that sits awkwardly alongside the tightening narrative.
What two decades of data show
According to Holz, market data stretching back roughly twenty years reveals no meaningful statistical relationship between interest rates and biotech stock performance. The confusion, he suggests, stems from the pandemic era, when near-zero rates coincided with an extraordinary surge in healthcare valuations. Investors came to treat that unusual convergence as a permanent rule rather than a one-off event.
Once that anomaly is stripped out of the two-decade record, the correlation between rates and biotech equities largely disappears. The recent softness in the sector, Holz contends, reflects a self-reinforcing investor perception rather than genuine fundamental deterioration.
Execution, not macro, decides winners
Holz points to company-specific execution and portfolio diversification as the true determinants of sector performance. Novo Nordisk offers a case in point: its shares have fallen roughly 15% this year, largely because the market views Eli Lilly as the early leader in the obesity drug race. Beyond its flagship Wegovy and Cagrisema pipeline, Novo needs to demonstrate a broader therapeutic footprint through aggressive business development.
The company's attempt to acquire Metsera fell apart after Pfizer outbid it, but strategic transactions outside the core weight-loss category could still reshape its trajectory. Investors, Holz notes, are increasingly looking past single-theme narratives and placing greater value on active dealmaking and pipeline diversification than on weight-loss speculation alone.
A pivot toward pragmatic dealmaking
Leadership across large-cap pharma is shifting away from crowded mega-trends toward disciplined deal execution. While high-flying obesity pure-plays have stumbled, diversified giants such as Merck have rallied about 40% year-to-date following a series of targeted business development transactions. By completing five strategic deals over the past year, Merck has successfully reduced its reliance on Keytruda for topline growth.
By contrast, Lilly's smaller transactions have yet to deliver a meaningful lift to sales, and Novo's operational missteps have drawn skepticism from the market. For Holz, sustained revenue growth and disciplined M&A remain far more consequential drivers of biotechnology and pharmaceutical returns than the trajectory of Federal Reserve policy.
The takeaway for investors
For those watching biotech stocks, the message is straightforward. Rather than fixating on macro policy, long-term performance hinges on clinical milestone execution and disciplined capital allocation. Rate decisions will continue to dominate headlines, but the evidence Holz cites suggests they are a poor guide to which drug developers will outperform.
This article is for informational purposes only and does not constitute financial advice.
